Skip to main content

Table 2 Use of experimental antiretroviral drugs in a therapy initiation/change episode by demographic/epidemiological characteristics of patients and clinical and laboratory data at the time antiretroviral treatment (ART) initiation/change

From: Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis

  Therapy initiation/change episodes including an experimental antiretroviral Total therapy initiation/change episodes p-value
  In clinical trial
N (%)
In EAP a
N (%)
  
Total reported AIDS cases in the clinical centre     0.02
0-250 34 (2.2) 34 (2.2) 1.575  
251-500 54 (2.7) 46 (2.3) 2.004  
501-1000 54 (2.4) 42 (1.9) 2.212  
> 1000 50 (1.4) 78 (2.1) 3.650  
Type of clinical centre     0.05
Non-teaching hospital 113 (2.3) 118 (2.4) 4.993  
Teaching hospital 79 (1.8) 82 (1.8) 4.448  
Gender     0.80
Females 56 (1.9) 58 (2.0) 2.889  
Males 136 (2.1) 142 (2.2) 6.552  
Age at ART initiation/change     0.48
18-34 67 (2.5) 56 (2.1) 2.687  
35-39 48 (1.8) 60 (2.3) 2.609  
40-44 40 (2.0) 37 (1.9) 1.960  
> = 45 37 (1.7) 47 (2.2) 2.185  
Place of birth     0.36
Italy 178 (2.0) 191 (2.2) 8.774  
Other countries 14 (2.1) 9 (1.3) 667  
Years of education     0.22
< = 8 78 (1.7) 90 (1.9) 4.624  
9-13 55 (2.2) 56 (2.2) 2.530  
> 13 10 (2.3) 11 (2.5) 432  
Unknown 49 (2.6) 43 (2.3) 1.855  
Marital status     0.29
Never married 93 (1.9) 94 (1.9) 4.864  
Married 99 (2.2) 106 (2.3) 4.577  
Occupational status     0.53
Unemployed 47 (2.0) 47 (2.0) 2.345  
Employed 138 (2.1) 145 (2.2) 6.675  
Other 7 (1.7) 8 (1.9) 421  
HIV exposure category     0.08
Heterosexual 73 (2.0) 68 (1.9) 3.597  
Homosexual/Bisexual 48 (2.4) 58 (2.9) 2.010  
IDU (Active+Former) 56 (1.7) 65 (2.0) 3.237  
Other/Unknown 15 (2.5) 9 (1.5) 597  
Nadir CD4 cell count (cells/ml)     0.07
< 200 86 (2.0) 104 (2.4) 4348  
200-349 51 (1.7) 51 (1.7) 2965  
> = 350 55 (2.6) 45 (2.1) 2128  
Clinical and laboratory data at treatment initiation/change     
Clinical AIDS     0.10
No 161 (2.1) 151 (2.0) 7.600  
Yes 31 (1.7) 49 (2.7) 1.841  
CD4 cell count (cells/ml)     0.10
< 200 64 (2.7) 56 (2.3) 2387  
200-349 45 (1.8) 49 (2.0) 2444  
> = 350 83 (1.8) 95 (2.1) 4610  
HIV RNA (log 10 copies/ml)     < 0.001
< 2 22 (1.0) 31 (1.4) 2275  
2-3 48 (2.0) 53 (2.3) 2345  
> = 4 122 (2.5) 116 (2.4) 4812  
Presence of hepatic comorbidities     0.01
No 127 (2.4) 103 (1.9) 5313  
Yes 65 (1.6) 97 (2.3) 4128  
Presence of other b comorbidities     0.15
No 179 (2.1) 177 (2.1) 8384  
Yes 13 (1.2) 23 (2.2) 1057  
Number of experienced drugs     < 0.001
Naive 117 (3.2) 42 (1.2) 3.647  
3-4 44 (1.2) 74 (2.1) 3.524  
5-7 15 (0.9) 50 (3.0) 1.675  
> = 8 16 (2.7) 34 (5.7) 595  
Number of failed drugs     < 0.001
0-2 153 (2.3) 94 (1.4) 6.727  
3-4 26 (1.3) 62 (3.3) 2.047  
> = 5 13 (1.9) 44 (6.6) 667  
  1. a Expanded access program; b cardio-vascular/metabolic diseases or neoplasm